stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
85.78
1.60
+1.90%
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Net margin
Abivax SA Sponsored ADR's net margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2025) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 0.00% | 0.00 |
| Mar 2026 | 0.00% | 0.00 |
| Dec 2025 | 0.00% | 0.00 |
| Sep 2025 | 0.00% | 0.00 |
| 7 more quarters | Free account |
Against its own ten years
Low 0.00%
High 0.00%
Ten-year median
0.00%
Current reading's percentile
100
Net margin against peers
| Company | Net margin |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | 16.5% |
| ORKA Oruka Therapeutics, Inc. compare | 0.00% |
| PRAX Praxis Precision Medicines, Inc. compare | 0.00% |
| ABVX Abivax SA Sponsored ADR | 0.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| AXSM Axsome Therapeutics, Inc. compare | −18.2% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −47.8% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −70.6% |
| CYTK Cytokinetics, Incorporated compare | −686.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue